Advertisement

Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease

  • Salim S. Virani
    Correspondence
    Corresponding author: Tel: (713) 440-4410; fax: (713) 748-7359.
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas

    Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas

    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas

    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Texas
    Search for articles by this author
  • LeChauncy D. Woodard
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas
    Search for articles by this author
  • David J. Ramsey
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas
    Search for articles by this author
  • Tracy H. Urech
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas
    Search for articles by this author
  • Julia M. Akeroyd
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas
    Search for articles by this author
  • Tina Shah
    Affiliations
    Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas

    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
    Search for articles by this author
  • Anita Deswal
    Affiliations
    Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas

    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
    Search for articles by this author
  • Biykem Bozkurt
    Affiliations
    Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas

    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
    Search for articles by this author
  • Christie M. Ballantyne
    Affiliations
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas

    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Texas
    Search for articles by this author
  • Laura A. Petersen
    Affiliations
    Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center, Health Services Research and Development Center for Innovations, Houston, Texas
    Search for articles by this author
Published:October 11, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.09.041
      Studies have shown gender disparities in cholesterol care in patients with cardiovascular disease (CVD), with women less likely than men to have low-density lipoprotein cholesterol levels <100 mg/dl. Whether this is related to a lower evidence-based statin or high-intensity statin use is not known. We used a national cohort of 972,532 patients with CVD (coronary heart disease, peripheral artery disease, and ischemic stroke) receiving care in 130 Veterans Health Administration facilities from October 1, 2010, to September 30, 2011, to identify the proportion of male and female patients with CVD receiving any statin and high-intensity statin. Women with CVD (n = 13,371) were less likely than men to receive statins (57.6% vs 64.8%, p <0.0001) or high-intensity statins (21.1% vs 23.6%, p <0.0001). Mean low-density lipoprotein cholesterol levels (99 vs 85 mg/dl) were higher in women compared with men (p <0.0001). In adjusted models, female gender was independently associated with a lower likelihood of receiving statins (odds ratio 0.68, 95% confidence interval 0.66 to 0.71) or high-intensity statins (odds ratio 0.76, 95% confidence interval 0.73 to 0.80). The median facility-level rate of statin and high-intensity statin use among female patients (57.3% [interquartile range = 8.93%] for statin, 20% [interquartile range = 7.7%] for high-intensity statin use) showed significant variation. In conclusion, women with CVD are less likely to receive evidence-based statin and high-intensity statins compared with men, although, their use remains low in both genders. There is a significant facility-level variation in evidence-based statin or high-intensity statin use in female patients with CVD. With the “statin dose-based approach” proposed by the recent cholesterol guidelines, these results highlight areas for quality improvement.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baigent C.
        • Blackwell L.
        • Emberson J.
        • Holland L.E.
        • Reith C.
        • Bhala N.
        • Peto R.
        • Barnes E.H.
        • Keech A.
        • Simes J.
        • Collins R.
        • Cholesterol Treatment Trialists' (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • Whitney E.
        • Shapiro D.R.
        • Beere P.A.
        • Langendorfer A.
        • Stein E.A.
        • Kruyer W.
        • Gotto Jr., A.M.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Pedersen T.R.
        • Faergeman O.
        • Kastelein J.J.
        • Olsson A.G.
        • Tikkanen M.J.
        • Holme I.
        • Larsen M.L.
        • Bendiksen F.S.
        • Lindahl C.
        • Szarek M.
        • Tsai J.
        • Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
        High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        JAMA. 2005; 294: 2437-2445
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Shear C.
        • Barter P.
        • Fruchart J.C.
        • Gotto A.M.
        • Greten H.
        • Kastelein J.J.
        • Shepherd J.
        • Wenger N.K.
        • Treating to New Targets (TNT) Investigators
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Arnold S.V.
        • Spertus J.A.
        • Tang F.
        • Krumholz H.M.
        • Borden W.B.
        • Farmer S.A.
        • Ting H.H.
        • Chan P.S.
        Statin use in outpatients with obstructive coronary artery disease.
        Circulation. 2011; 124: 2405-2410
        • Virani S.S.
        • Woodard L.D.
        • Chitwood S.S.
        • Landrum C.R.
        • Urech T.H.
        • Wang D.
        • Murawsky J.
        • Ballantyne C.M.
        • Petersen L.A.
        Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease.
        Am Heart J. 2011; 162: 725-732
        • Stone N.J.
        • Robinson J.
        • Lichtenstein A.H.
        • Bairey Merz C.N.
        • Blum C.B.
        • Eckel R.H.
        • Goldberg A.C.
        • Gordon D.
        • Levy D.
        • Lloyd-Jones D.M.
        • McBride P.
        • Schwartz J.S.
        • Shero S.T.
        • Smith Jr., S.C.
        • Watson K.
        • Wilson P.W.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Woodard L.D.
        • Landrum C.R.
        • Urech T.H.
        • Profit J.
        • Virani S.S.
        • Petersen L.A.
        Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement.
        J Am Geriatr Soc. 2012; 60: 193-201
        • Virani S.S.
        • Woodard L.D.
        • Landrum C.R.
        • Pietz K.
        • Wang D.
        • Ballantyne C.M.
        • Petersen L.A.
        Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines.
        Am Heart J. 2011; 161: 1140-1146
        • Woodard L.D.
        • Landrum C.R.
        • Urech T.H.
        • Wang D.
        • Virani S.S.
        • Petersen L.A.
        Impact of clinical complexity on the quality of diabetes care.
        Am J Manag Care. 2012; 18: 508-514
        • Virani S.S.
        • Wang D.
        • Woodard L.D.
        • Chitwood S.S.
        • Landrum C.R.
        • Zieve F.J.
        • Ballantyne C.M.
        • Petersen L.A.
        Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care.
        J Clin Lipidol. 2012; 6: 545-552
        • Woodard L.D.
        • Urech T.
        • Landrum C.R.
        • Wang D.
        • Petersen L.A.
        Impact of comorbidity type on measures of quality for diabetes care.
        Med Care. 2011; 49: 605-610
        • Petersen L.A.
        • Pietz K.
        • Woodard L.D.
        • Woodard L.D.
        • Byrne M.
        Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes.
        Med Care. 2005; 43: 61-67
        • Petersen L.A.
        • Woodard L.D.
        • Henderson L.M.
        • Urech T.H.
        • Pietz K.
        Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients?.
        Circulation. 2009; 119: 2978-2985
        • Mora S.
        • Glynn R.J.
        • Hsia J.
        • MacFadyen J.G.
        • Genest J.
        • Ridker P.M.
        Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
        Circulation. 2010; 121: 1069-1077
        • Truong Q.A.
        • Murphy S.A.
        • McCabe C.H.
        • Armani A.
        • Cannon C.P.
        Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
        Circ Cardiovasc Qual Outcomes. 2011; 4: 328-336
      1. Available at: http://vaww.car.rtp.med.va.gov/programs/pm/performance.aspx. Accessed on January 2, 2014.